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Success following allogeneic hematopoietic cell
transplantation (HSCT) is ultimately determined by
the ability to achieve sustained engraftment and im-
mune reconstitution, eradication of the abnormal or
malignant cells responsible for the patient’s disease,
and control of graft-versus-host disease (GVHD).
GVHD, an immune-mediated reaction initiated by
donor T cells in response to host alloantigen, is the
cause of significant morbidity and death in many pa-
tients. Genetic matching for HLA, the human major
histocompatibility complex (MHC), located on chro-
mosome 6p21, has for several years become well estab-
lished as a requirement for optimal HSCT outcome
[1]. Despite complete matching for all variation span-
ning 4 Mb of DNA across the MHC, acute GVHD
(aGVHD), chronic GVHD (cGVHD), and trans-
plant-related mortality (TRM) occurs in a significant
number of HLA identical sibling donor transplants.The Alloimmune Reaction
Clinical GVHD results from an alloimmune reac-
tion that occurs when immune competent donor T
cells are transplanted to an immune compromised
host and the genetic differences between donor and re-
cipient are sufficient to induce T cell activation [2].
The genetic differences responsible for an allograft
reaction encode polymorphic cellular proteins called
histocompatibility antigens [3]. The strongest histo-
compatibility antigens are encoded by the class I and
class II genes of the MHC, or HLA, but there areThe Fred Hutchinson Cancer Research Center and the
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that encode cellular peptides capable of generating sig-
nificant alloimmune responses if variation in the gene
product can be detected by T cells. These ‘‘allo’’ pep-
tides are called minor histocompatibility antigens
(mHA) [4]. Although HLA identical siblings share
50% of their genome, the mHA disparity is sufficient
to cause clinically significant aGVHD in 30% to
40% of cases. Despite HLA matching among unre-
lated donor-recipient pairs, disparity for non-MHC
mHA is greater because the recipient and donor do
not share the same parental chromosomes [5].
Pathogenesis of GVHD
The incidence, severity, and duration of GVHD
following HSCT vary substantially from patient to pa-
tient [6-11]. Differences in GVHD phenotype can re-
sult from both inherited and clinical or environmental
factors including type of disease, disease status, treat-
ment history, HLA match, age, sex of donor and pa-
tient (and sex match), and the type of conditioning
therapy administered prior to transplant [8,12,13].
High-dose cytotoxic conditioning can increase the
risk of aGVHD by causing mucosal injury, which facil-
itates translocation of endotoxin into the bloodstream,
suppressing T cell and natural killer (NK) cell-medi-
ated allograft resistance and activating antigen-pre-
senting cells (APCs) in the recipient. Within hours
after transplantation, GVHD begins with the presen-
tation of alloantigens by host dendritic cells, followed
by activation of donor T cells, which undergo clonal
expansion and migration into various lymphoid organs
and target tissues [14]. The antihost alloimmune reac-
tion is largely driven by the leakage of lipopolysaccha-
ride (LPS) across the gut wall [15], and further
amplified by multiple components of the immune sys-
tems, including NK cells, monocytes, macrophages,
and proinflammatory cytokines [16-20].
Proteomic Analysis of aGVHD and TRM
Several studies have described changes in plasma
proteins that correlate with the risk of aGVHD,e1
e2 Biol Blood Marrow Transplant 15:1-7, 2009J. A. HansencGVHD, and TRM (summarized in Table 1). Al-
though there are common discoveries among several
of these studies, there are also findings that have not in-
dependently replicated, and for this reason true posi-
tives have not been clearly defined. There remains
a great need for further and rigorously conducted stud-
ies that achieve both validation and also identification
of the clinical covariables that it must be known to fully
interpret and reliably implement biomarker data, both
proteomic and genomic, into clinical risk assessment
algorithms and preemptive therapies.
Genomic Analysis GVHD and TRM
Several studies over the last 10 years have identified
genetic polymorphisms associated with GVHD and
TRM (summarized in Table 2). Initially, these investi-
gations focused on well-known genes encoding proin-
flammatory or immune modulating cytokines
including IL1A, IL1B, IL1RN, IL6, IL10, INFG,
TGFB, and TNF [21-34]. Subsequent studies have ex-
amined additional genes for variation associated with
HSCT outcomes including CTLA4, ESR1, IL2,
IL7R, IL8, IL10RB, IL18, NOD2, and VDR [28,35-43].
Unfortunately, the results of most of these single-
center studies have not been independently validated
by others in separate patient populations. Lack of val-
idation or inconsistency in these results may be due
largely to lack of statistical power because many of
the original studies were based on relatively small
numbers (\200-300 cases). Nevertheless, these results
have been sufficiently compelling to warrant addi-
tional study. Comprehensive critical reviews of thisTable 1. Summary of Published Changes in Plasma Proteins Assoc
Protein aGVHD
IL1-RN
IL2R Miyamoto et al. 1996 [55]; Grimm et al. 1998 [56]; Foley et al
[57]; Nakamura et al. 2000 [58]; Visentainer et al. 2003 [59
Shaiegan et al. 2006 [60]; Paczesny et al. 2008 [61]
IL-6 Imamura et al. 1994 [63]
IL-8 Uguccioni et al. 1993 [64]; Paczesny et al. 2008 [61]
IL-10 Liem et al. 1998 [54]
IL-12 Nakamura et al. 2000 [58]; Mohty et al. 2005 [66]
IL-15 Sakata et al. 2001 [67]
IL-18 Nakamura et al. 2000 [58]; Fujimori et al. 2000 [68];
Shaiegan et al. 2006 [60]; Luft et al. 2007 [69]
BAFF
CD13
CCL8 Hori et al. 2008 [70]
CXCL10 Piper et al. 2007 [71]
HGF Okamoto et al. 2001 [72]; Paczesny et al. 2008 [61]
IFNG Imamura et al. 1994 [63]; Nakamura et al. 2000 [58]
TNF Holler et al. 1990 [73]; Symington et al. 1990 [74];
Imamura et al. 1994 [63]
TNFR Or 1996 et al. [75]; Kitko et al. 2008 [76]; Choi et al. 2008 [7
Paczesny et al. 2008 [61]
Syndecan-1 Seidel et al. 2003 [78]
anti-dsDNA
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versu
*Refer to original publication for additional details.research have been recently published [44,45], and
other current papers have addressed the potential
impact of developments in genomic sciences and the
opportunity for expanding HSCT outcomes research
to genome-wide discovery [1,46].
Genome-Wide Association Studies (GWAS)
The remarkable development in recent years of
methods and tools for the characterization of the entire
human genome has dramatically broadened the oppor-
tunity for the genetic analysis of disease. The recent
completion of the human genome map [47,48] and
the development of dense single nucleotide polymor-
phism (SNP) marker maps of the genome [49,50], as
well as development of massively parallel genotyping
technologies [51-53], have made it possible to screen
genes in an unbiased manner for polymorphisms that
correlate with any well-defined phenotype, disease sta-
tus, or relevant quantitative trait. This is particularly
important when considering complex traits that char-
acterize HCT complications and outcomes. Consider-
ation of the entire genome in an unbiased fashion
permits the discovery of genetic factors that would
have never been considered otherwise.
State-of-the-Art Genomic and Proteomic
Studies of GVHD and Mortality
The 3 papers that follow this Introduction are
summaries of the oral presentations that will be given
during the Genomics and Proteomics Scientific
Session of the 2009 BMT Tandem meetings. These
papers are each timely progress reports of ouriated with Acute GVHD, TRM, and Chronic GVHD*
TRM cGVHD
Liem et al. 1998 [54]
. 1998
];
Liem et al. 1998 [54];
Fujii et al. 2008 [62]
Schots et al. 2003 [65]
Liem et al. 1998 [54];
Visentainer et al. 2003 [59]
Fujii et al. 2008 [62]
Fujii et al. 2008 [62]
7];
Fujii et al. 2008 [62]
s-host disease; TRM, transplant-related mortality.
Table 2. Genetic Variation in Immune Response Genes Associated with Acute GVHD, TRM, and Chronic GVHD
Gene
HSCT-
Associated
Phenotype
Study
Population
(N)*
VNTR or SNP
Discovery and Supporting
Reference(s)‡
Investigators Reporting
Nonsignificant Results‡Alias Location Alleles rs Number
CTLA4
(CD152)
aGVHD
and
survival
MRD (536) +49 (d),
CT60 (d)†
A/G, G/A rs231775,
rs3087243
Perez-Garcia et al. 2007 [41]
cGVHD +49/GG A/G rs231775 Azarian et al. 2007 [42]
ESR1 aGVHD MRD (108) VNTR, PvuII
and XbaI
intron 1 — — Middleton et al. 2003 [35]
FAS aGVHD MRD (160) 2670 (p) promoter A/G — Mullighan et al. 2004 [29]
IFNG aGVHD MRD (49) VNTR intron 1 na — Middleton et al. 1998 [21]
aGVHD MRD (100) 874 T/A — — Socie 2001 [23]
IL1A cGVHD MRD (115) 2899, VNTR promoter,
intron 6
C/T, allele 2 — — Cullup et al. 2003 [27] —
aGVHD
and TRM
URD(426) 2889 promoter C/T — — Mehta 2007 [34]
IL1B aGVHD MRD 2511 (p) promoter T/C rs16944 MacMillan et al. 2003[28] —
aGVHD MRD (570) 2511 (p/d) promoter C/T rs16944 — Lin 2003 [26]
IL1RN aGVHD MRD (99) VNTR intron 1 — na Cullup et al. 2001 [24] —
aGVHD
and
cGVHD
MRD (107) VNTR (d) intron 2 absence of allele *2 — Rocha et al. 2002 [25] —
MRD (570) 9261 (p/d) intron 1 G/A 448341 — Lin 2003 [26]
IL2 aGVHD URD (95) 2333 (p) promoter T/G rs2069762 MacMillan Transplant 2003 [43] —
IL6 aGVHD MRD (160) 2174 (d) promoter G/C rs1800795 Mullighan et al. 2004 [29] —
aGVHD ND (93) 2174 (p/d) promoter G/C rs1800795 Karabon et al. 2005 [31] —
cGVHD 2174 promoter G/C rs1800795 Cavet et al. 1999 [22] —
cGVHD MRD (100) 2174 (p) promoter G/C Socie et al. 2001 [23] —
aGVHD,
cGVHD,
TRM
MRD (570) 2174 (d) promoter G/C rs1800795 — Lin 2003 [26]
IL7R TRM MURD (75) +1237(p) cSNP A/G — Shamim et al. 2006 [40] —
TRM MRD (100) +510,+1237,+
2087,+3101
cSNPs C/T,A/G,C/T,A/G — — Shamim 2006 [40]
IL10 aGVHD MRD (49) IL10G;§ promoter — — Middleton et al. 1998 [21] —
aGVHD MRD (144) IL10/21082,
IL1021064§
promoter A/G — Cavet et al. 1999 [22] —
aGVHD MRD (100) hap¶ promoter G-C-C — Socie et al. 2001 [23] —
aGVHD MRD (993) 2592 (p) and
hap (p)¶
promoter C/A, A-T-A Lin et al. 2003 [26] —
aGVHD MRD (160) ATA hap(p) promoter — Mullighan 2004 [29]
cGVHD MRD (107) 21082*G/G(p) promoter A/G — Rocha et al. 2002 [25] —
cGVHD ATA hap(p) promoter Mullighan et al. 2004 [29] —
TRM URD (182) IL10R2§-SNP
hap (d)¶
promoter G-C-C Keen et al. 2004 [30] —
IL10RB aGVHD MRD (993) c238 (d) exon Lin et al. 2005 [37] —
IL18 Survival URD (157) GCG hap(p) Cardodo et al. 2004 [38] —
(Continued )
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Table 2. (Continued )
Gene
HSCT-
Associated
Phenotype
Study
Population
(N)*
VNTR or SNP
Discovery and Supporting
Reference(s)‡
Investigators Reporting
Nonsignificant Results‡Alias Location Alleles rs Number
NOD2 aGVHD
and
TRM
SNP8, 12, 3 intragenic G/A, G/C,
insertion
rs2066844, rs2066845,
rs2066847
Holler 2004, 2006 [36,39] —
TNF aGVHD MRD (49) TNFd^,** VNTR na Middleton et al. 1998 [21]
TRM MRD (144) TNFd** VNTR na Cavet et al. 1999 [22]
aGVHD MRD (100)
MRD (570)
MRD (160)
2308 7 promoter G/A rs1800629 — Socie 2001 [23];
Lin 2003 [26];
Mullighan 2004 [29]
TRM URD (182) TNFd and 21031 promoter:
VNTR
and SNP
TNFd*4/
21031*C hap
— Keen et al. 2004 [30] —
aGVHD & TRM MRD (160) 488 7 Mullighan et al. 2004 [29] —
TNFRII cGVHD MRD (104) codon 196 exon 6 T/G Stark et al. 2003 [79] —
VDR aGVHD and TRM MRD (88) VNTR (d) intron 8 Middleton et al. 2002 [80] —
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; HCST, hematopoietic cell transplantation; VNTR, variable number tandum repeat; SNP, single nucleotide polymorphisms;
TRM, transplant-related mortality.
*Study population: MRD indicates HLA matched related donor; ND, not defined; URD, unrelated donor.
†p indicates patient; d, donor.
‡Refer to original publication(s) for additional details.
§IL10G and IL10R are a microsatellites located in and nearby the IL10 gene.
¶IL10 promoter region haplotype, positions: 21082/2819/2592.
^TNFd is a microsatellite in the TBF region.
**MRD cases, because they are HLA identical, share the same TNF genotypes.
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GVHD and TRM. The paper by Sophie Paczesny, Ja-
mie Ferrara, and team provides model example of the
rigorous 2-phase, discovery and validation, proteomic
study of changes in plasma proteins associated with the
development of aGVHD. The technology used for the
discovery phase used an antibody array containing an-
tibodies specific for 120 human proteins including
acute phase reactants, cytokines, angiogenic factors,
tumor markers, leukocyte adhesion molecules, and
metalloproteinases and their inhibitors. The papers
by Seishi Ogawa et al. and Jason Chien et al. describe
preliminary discovery data from 2 of the first large
whole genome scans performed on DNA from both
recipient and donor as a comprehensive approach to
examining genetic disparity and GVHD (Ogawa
et al.), and the association of genetic variation with
transplant outcomes including Gram-negative bacter-
emia and bronchiolitis obliterans.ACKNOWLEDGMENTS
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